Patents by Inventor Wenda C. Carlyle
Wenda C. Carlyle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190231691Abstract: Drug delivery systems are disclosed which include a drug in dry powder form and a biodegradable or metabolizable carrier having an average particle size of less than about 1 mm for delivery of the drug to a particular location in the body and for providing for the timed elution of the drug at that location, preferably by exhibiting a linear drug elution profile for a sustained drug release period of at least 30 days. Methods for manufacturing these drug delivery systems are also disclosed.Type: ApplicationFiled: April 10, 2019Publication date: August 1, 2019Applicant: Micell Technologies, Inc.Inventor: Wenda C. Carlyle
-
Patent number: 10293050Abstract: Provided is a drug delivery composition comprising at least one polymer and at least one active agent; wherein the active agent is present in crystalline form on at least one region of an outer surface of the composition and wherein active agent surface content is adjusted to provide a selected active agent release profile.Type: GrantFiled: March 28, 2017Date of Patent: May 21, 2019Assignee: Micell Technologies, Inc.Inventors: James B. McClain, Wenda C. Carlyle, Charles Douglas Taylor
-
Publication number: 20180326071Abstract: A coated balloon device for stabilizing a section of a blood vessel in a living subject is disclosed. The coating layer of the coated balloon comprises a phenolic compound having a plurality of phenolic groups connected to form a hydrophobic core with peripheral phenolic hydroxyl groups. The coating layer of the coated balloon may contain a hydrophilic polymer to facilitate the release of the phenolic compound. The balloon in general is made of a compliant polymer for atraumatic contact with the blood vessel. In some embodiments, the coating of the coated balloon device further comprises a hydrophilic undercoat layer between the balloon and the coating layer. In some embodiments, the coated balloon device further comprises a sacrificial top coating that dissolves upon delivery into the section of the blood vessel and comprises a hydrophilic composition including sugar, sugar derivatives, or a combination thereof.Type: ApplicationFiled: April 6, 2018Publication date: November 15, 2018Inventors: Matthew F. Ogle, Wenda C. Carlyle, Edward J. Anderson, Kishore Udipi
-
Patent number: 9937255Abstract: A coated balloon device for stabilizing a section of a blood vessel in a living subject is disclosed. The coating layer of the coated balloon comprises a phenolic compound having a plurality of phenolic groups connected to form a hydrophobic core with peripheral phenolic hydroxyl groups. The coating layer of the coated balloon may contain a hydrophilic polymer to facilitate the release of the phenolic compound. The balloon in general is made of a compliant polymer for atraumatic contact with the blood vessel. In some embodiments, the coating of the coated balloon device further comprises a hydrophilic undercoat layer between the balloon and the coating layer. In some embodiments, the coated balloon device further comprises a sacrificial top coating that dissolves upon delivery into the section of the blood vessel and comprises a hydrophilic composition including sugar, sugar derivatives, or a combination thereof.Type: GrantFiled: May 17, 2012Date of Patent: April 10, 2018Assignee: NECTERO MEDICAL, INC.Inventors: Matthew F. Ogle, Wenda C. Carlyle, Edward J. Anderson, Kishore Udipi
-
Publication number: 20170196982Abstract: Provided is a drug delivery composition comprising at least one polymer and at least one active agent; wherein the active agent is present in crystalline form on at least one region of an outer surface of the composition and wherein active agent surface content is adjusted to provide a selected active agent release profile.Type: ApplicationFiled: March 28, 2017Publication date: July 13, 2017Applicant: Micell Technologies, Inc.Inventors: James B. McClain, Wenda C. Carlyle, Charles Douglas Taylor
-
Patent number: 9636309Abstract: Provided is a drug delivery composition comprising at least one polymer and at least one active agent; wherein the active agent is present in crystalline form on at least one region of an outer surface of the composition and wherein active agent surface content is adjusted to provide a selected active agent release profile.Type: GrantFiled: September 9, 2011Date of Patent: May 2, 2017Assignee: Micell Technologies, Inc.Inventors: James B. McClain, Charles Douglas Taylor, Wenda C. Carlyle
-
Publication number: 20170065521Abstract: Drug delivery systems are disclosed which include a drug in dry powder form and a biodegradable or metabolizable carrier having an average particle size of less than about 1 mm for delivery of the drug to a particular location in the body and for providing for the timed elution of the drug at that location, preferably by exhibiting a linear drug elution profile for a sustained drug release period of at least 30 days. Methods for manufacturing these drug delivery systems are also disclosed.Type: ApplicationFiled: September 9, 2016Publication date: March 9, 2017Applicant: Micell Technologies, Inc.Inventor: Wenda C. Carlyle
-
Publication number: 20160271303Abstract: Provided herein is a device comprising a stent and a coating on the stent; wherein the coating comprises at least one polymer and at least one active agent; wherein at least part of the active agent is in crystalline form.Type: ApplicationFiled: May 31, 2016Publication date: September 22, 2016Applicant: Micell Technologies, Inc.Inventors: James B. McClain, Charles Douglas Taylor, Wenda C. Carlyle
-
Publication number: 20150087671Abstract: A drug delivery composition including a lipophilic agent or a biologic agent and a polymer wherein the lipophilic agent exhibits sustained release and wherein there is less than 35% agent release within the first hour of elution. A drug delivery composition including a lipophilic agent or a biologic agent and a polymer wherein the elution profile is substantially linear, and wherein there is less than 35% agent release within the first hour of elution. The lipophilic agent may be crystalline and the biologic agent may be in active form.Type: ApplicationFiled: May 16, 2013Publication date: March 26, 2015Inventors: James B. McClain, Charles Douglas Taylor, Wenda C. Carlyle
-
Patent number: 8911468Abstract: The methods and devices disclosed herein pertain to the percutaneous treatment of various forms of aortic dissection by at least partially filling the false lumen of the aortic dissection with a stabilization agent percutaneously and steps to decrease the size of the false lumen using the devices. Fluid maybe aspirated from the false lumen to decrease the volume of the false lumen. And the entrance opening between the true lumen and the false lumen may be sealed with a sealing agent such as a biocompatible adhesive. The medical devices disclosed herein generally comprise an extendable sealing element that is used in conjunction with a catheter to expand the true lumen while reducing the size of the false lumen. The device has the ability to aspirate and/or deliver fluid containing the stabilization agent into the false lumen.Type: GrantFiled: January 31, 2012Date of Patent: December 16, 2014Assignee: Vatrix Medical, Inc.Inventors: Matthew F. Ogle, Edward J. Anderson, Todd D. Reil, Wenda C. Carlyle
-
Publication number: 20140257465Abstract: Provided herein is a device comprising a stent and a coating on the stent; wherein the coating comprises at least one polymer and at least one active agent; wherein at least part of the active agent is in crystalline form.Type: ApplicationFiled: August 10, 2012Publication date: September 11, 2014Inventors: James B. McClain, Charles Douglas Taylor, Wenda C. Carlyle
-
Patent number: 8439674Abstract: Systems and methods are disclosed for intra-oral delivery of drugs.Type: GrantFiled: December 13, 2011Date of Patent: May 14, 2013Assignee: Align Technology, Inc.Inventors: Chunhua Li, Wenda C. Carlyle, Philippe De Smedt, Amir Abolfathi, Eric E. Kuo, Robert E. Tricca, Jennifer C. Chen, Benjamin M. Wu
-
Publication number: 20120323211Abstract: A coated balloon device for stabilizing a section of a blood vessel in a living subject is disclosed. The coating layer of the coated balloon comprises a phenolic compound having a plurality of phenolic groups connected to form a hydrophobic core with peripheral phenolic hydroxyl groups. The coating layer of the coated balloon may contain a hydrophilic polymer to facilitate the release of the phenolic compound. The balloon in general is made of a compliant polymer for atraumatic contact with the blood vessel. In some embodiments, the coating of the coated balloon device further comprises a hydrophilic undercoat layer between the balloon and the coating layer. In some embodiments, the coated balloon device further comprises a sacrificial top coating that dissolves upon delivery into the section of the blood vessel and comprises a hydrophilic composition including sugar, sugar derivatives, or a combination thereof.Type: ApplicationFiled: May 17, 2012Publication date: December 20, 2012Inventors: Matthew F. Ogle, Wenda C. Carlyle, Edward J. Anderson, Kishore Udipi
-
Publication number: 20120197284Abstract: The methods and devices disclosed herein pertain to the percutaneous treatment of various forms of aortic dissection by at least partially filling the false lumen of the aortic dissection with a stabilization agent percutaneously and steps to decrease the size of the false lumen using the devices. Fluid maybe aspirated from the false lumen to decrease the volume of the false lumen. And the entrance opening between the true lumen and the false lumen may be sealed with a sealing agent such as a biocompatible adhesive. The medical devices disclosed herein generally comprise an extendable sealing element that is used in conjunction with a catheter to expand the true lumen while reducing the size of the false lumen. The device has the ability to aspirate and/or deliver fluid containing the stabilization agent into the false lumen.Type: ApplicationFiled: January 31, 2012Publication date: August 2, 2012Inventors: Matthew F. Ogle, Edward J. Anderson, Todd D. Reil, Wenda C. Carlyle
-
Publication number: 20120082950Abstract: Systems and methods are disclosed for intra-oral delivery of drugs.Type: ApplicationFiled: December 13, 2011Publication date: April 5, 2012Applicant: Align Technology, Inc.Inventors: Chunhua Li, Wenda C. Carlyle, Philippe De Smedt, Amir Abolfathi, Eric E. Kuo, Robert E. Tricca, Jennifer C. Chen, Benjamin M. Wu
-
Publication number: 20120064124Abstract: Provided is a drug delivery composition comprising at least one polymer and at least one active agent; wherein the active agent is present in crystalline form on at least one region of an outer surface of the composition and wherein active agent surface content is adjusted to provide a selected active agent release profile.Type: ApplicationFiled: September 9, 2011Publication date: March 15, 2012Applicant: MICELL TECHNOLOGIES, INC.Inventors: James B. McClain, Charles Douglas Taylor, Wenda C. Carlyle
-
Patent number: 8075309Abstract: Systems and methods are disclosed for intra-oral delivery of drugs. One method embodiment includes providing a dental device with one or more reservoirs, supplying at least one of the reservoirs with the one or more substances, and fluidly releasing the one or more substances from at least one reservoir into an oral structure at different preselected doses at different predetermined time periods and in a predetermined sequence.Type: GrantFiled: October 31, 2007Date of Patent: December 13, 2011Assignee: Align Technology, Inc.Inventors: Chunhua Li, Wenda C. Carlyle, Philippe De Smedt, Amir Abolfathi, Eric E. Kuo, Robert E. Tricca, Jennifer C. Chen, Benjamin M. Wu
-
Patent number: 7722671Abstract: A polypeptide growth factor is associated with a substrate to promote population of the substrate with endothelial cells. In a preferred approach, the growth factor is associated with the substrate by crosslinking under suitably mild conditions such that the growth factor is active following the crosslinking process. Thus, a prosthesis is formed with growth factor crosslinked to the substrate.Type: GrantFiled: November 5, 1998Date of Patent: May 25, 2010Assignee: St. Jude Medical, Inc.Inventors: Wenda C. Carlyle, Sheila J. Kelly, Matthew F. Ogle
-
Publication number: 20080293007Abstract: Systems and methods are disclosed for intra-oral delivery of drugs.Type: ApplicationFiled: October 31, 2007Publication date: November 27, 2008Inventors: Chunhua Li, Wenda C.. Carlyle, Philippe De Smedt, Amir Abolfathi, Eric E. Kuo, Robert E. Tricca, Jennifer C. Chen, Benjamin M. Wu
-
Patent number: 6726718Abstract: A prosthesis is formed from a biocompatible material having one or more associated cell adhesion stimulating proteins. The biocompatible material can be a ceramic material or a carbon coated material. The cell adhesion stimulating protein can be a structural protein or a polypeptide growth factor, such as vascular endothelial growth factor. Viable cells can be adhered in vivo or in vitro to the biocompatible material with the cell adhesion stimulating protein.Type: GrantFiled: December 13, 1999Date of Patent: April 27, 2004Assignee: St. Jude Medical, Inc.Inventors: Wenda C. Carlyle, Avrom M. Brendzel